Last reviewed · How we verify
Hyperpolarized xenon 129
Hyperpolarized xenon 129 is a Hyperpolarized gas contrast agent Small molecule drug developed by Y. Michael Shim, MD. It is currently FDA-approved for Pulmonary MRI imaging in patients with chronic obstructive pulmonary disease (COPD), Assessment of regional lung ventilation and perfusion, Evaluation of asthma and other obstructive airway diseases. Also known as: 129HxeMRI, 129Xe.
Hyperpolarized xenon-129 is an inhaled contrast agent that enhances lung MRI by providing increased signal from ventilated airspaces, enabling detailed visualization of pulmonary function and gas exchange.
Hyperpolarized xenon-129 is an inhaled contrast agent that enhances lung MRI by providing increased signal from ventilated airspaces, enabling detailed visualization of pulmonary function and gas exchange. Used for Pulmonary MRI imaging in patients with chronic obstructive pulmonary disease (COPD), Assessment of regional lung ventilation and perfusion, Evaluation of asthma and other obstructive airway diseases.
At a glance
| Generic name | Hyperpolarized xenon 129 |
|---|---|
| Also known as | 129HxeMRI, 129Xe |
| Sponsor | Y. Michael Shim, MD |
| Drug class | Hyperpolarized gas contrast agent |
| Modality | Small molecule |
| Therapeutic area | Pulmonary/Respiratory Imaging |
| Phase | FDA-approved |
Mechanism of action
Xenon-129 is a noble gas that is hyperpolarized (aligned nuclear spins) to dramatically increase its magnetic resonance signal. When inhaled, it distributes throughout ventilated lung regions and can diffuse across the alveolar-capillary membrane into red blood cells and tissue, allowing MRI to visualize regional ventilation, perfusion, and gas exchange in unprecedented detail without ionizing radiation.
Approved indications
- Pulmonary MRI imaging in patients with chronic obstructive pulmonary disease (COPD)
- Assessment of regional lung ventilation and perfusion
- Evaluation of asthma and other obstructive airway diseases
Common side effects
- Minimal adverse events reported; generally well-tolerated
Key clinical trials
- Developing Hyperpolarized Gas MRI Signatures to Detect and Manage Acute Cellular Rejection (PHASE2)
- Dissolved Phase HXe-129 MRI: A Novel Biomarker to Quantify Pulmonary Pathology (PHASE2, PHASE3)
- Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease (PHASE2)
- 129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) (PHASE2)
- Xenon MRI and Progressive ILD (PHASE2)
- 129 Xenon Imaging in Patients Treated With Sotatercept (PHASE2)
- Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity (PHASE1)
- Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperpolarized xenon 129 CI brief — competitive landscape report
- Hyperpolarized xenon 129 updates RSS · CI watch RSS
- Y. Michael Shim, MD portfolio CI
Frequently asked questions about Hyperpolarized xenon 129
What is Hyperpolarized xenon 129?
How does Hyperpolarized xenon 129 work?
What is Hyperpolarized xenon 129 used for?
Who makes Hyperpolarized xenon 129?
Is Hyperpolarized xenon 129 also known as anything else?
What drug class is Hyperpolarized xenon 129 in?
What development phase is Hyperpolarized xenon 129 in?
What are the side effects of Hyperpolarized xenon 129?
Related
- Drug class: All Hyperpolarized gas contrast agent drugs
- Manufacturer: Y. Michael Shim, MD — full pipeline
- Therapeutic area: All drugs in Pulmonary/Respiratory Imaging
- Indication: Drugs for Pulmonary MRI imaging in patients with chronic obstructive pulmonary disease (COPD)
- Indication: Drugs for Assessment of regional lung ventilation and perfusion
- Indication: Drugs for Evaluation of asthma and other obstructive airway diseases
- Also known as: 129HxeMRI, 129Xe
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing